Ratio of apoa2 to HDLc or Equivalents thereof, Risk Markers for Cardiovascular Disease

(canceled)

(canceled)

A method of characterizing the risk of experiencing a subsequent acute cardiovascular event in a subject who has experienced one or more acute adverse cardiovascular events, comprising:

• determining the ratio of apoA2 to HDLc or equivalents thereof in a biological sample taken from the subject at an initial time and in a corresponding biological sample taken from the subject at a subsequent time,
• comparing the ratio of apoA2 to HDLc or equivalents thereof in a biological sample taken from the subject at an initial time to the ratio of apoA2 to HDLc or equivalents thereof in a biological sample taken from the subject at a subsequent time,
• wherein an increase in the ratio of apoA2 to HDLc or equivalents thereof in a biological sample taken at the subsequent time as compared to the initial time indicates that a subject's risk of experiencing a subsequent adverse cardiovascular event has increased.

(canceled)

A method for characterizing a subject's risk of having cardiovascular disease, comprising:

• identifying at least one genetic determinant of apoA2 level in a test subject, the genetic determinant selected from the group consisting of rs1262269 and rs70753770 SNPs,
• wherein, if the test subject carries even one allele of an at risk SNP, which is associated with higher apoA2 levels, the test subject is at increased risk of having or developing CVD, and therefore at increased risk of experiencing CVD complications, a MACE, or both.